MaSTherCell S.A. (Manufacturing Synergies for Therapeutic Cells)

https://www.masthercell.com

MaSTherCell S.A. is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. MaSTherCell is a subsidiary of MaSTherCell Global Inc.– a gathering of MaSTherCell in Belgium, Atvio Biotech Ltd., an Israel-based CDMO, and Curecell Co. Ltd., a Korea-based CDMO partner. Masthercell Global is majority-owned by Orgenesis Inc. (Nasdaq:ORGS), a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 diabetes. At the heart of MaSTherCell is a team of highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. The company operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. *

	Start	2011-01-01 established
	Group	Catalent (Group)
	Industry	cell therapy
	Industry 2	contract manufacturing (biologicals)
	Person	Bedoret, Denis (Imcyse 202009– CEO before MaSTherCell + Quality Assistance SA + McKinsey & Co)

	Region	Gosselies
	Country	Belgium
	Street	48 Rue Auguste Piccard
	City	6041 Gosselies
	Tel	+32-71-347629
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2020-02-03)

		* Document for »About Section«: MaSTherCell S.A.. (10/1/18). "Press Release: KangStem Biotech Selects MaSTherCell for GMP Manufacturing of Furestem-AD in Europe". Seoul & Gosselies.

		Record changed: 2024-02-12